Review outlines the evolution and clinical selection of molecular oncology assays
The review examines the three-decade evolution of clinically available molecular assays for oncology, encompassing DNA, RNA, and protein-based platforms. Investigators note that tumor molecular profiling is increasingly identifying limitations in traditional histopathologic classification while enabling personalized treatment strategies. The authors emphasize that diagnostic laboratories and oncology providers must understand the validated options, advantages, and limitations of each assay to select the most appropriate test for individual patients. This overview serves as a practical reference for integrating molecular diagnostics into routine oncology care.
The original study
Understanding the Landscape of Clinically Available Molecular Testing.
- Authors
- Elvin JA
- Journal
- Hematology/oncology clinics of North America
- Type
- Journal Article, Review
- PMID
- 42686323
Original abstract
Over the past three decades, the landscape of clinically available molecular tests has evolved due to advancements in basic science cancer research and the subsequent utilization of this knowledge to develop DNA, RNA, and protein-based molecular assays for oncology that can be employed for routine clinical use in diagnostics laboratories. Molecular testing of tumors is revealing gaps in previous histopathologic classification systems and opportunities for new, personalized treatment paradigms. Awareness of validated molecular assay options and their general advantages and limitations is crucial for oncology care providers to ensure the optimal test(s) are selected for each patient's circumstances.